This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-19 and is reviewed periodically as new material appears.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Their isotopic signatures indicate that they grew up in a temperate environment consuming mostly C3 plants, but some C4 The study argued that these individuals were from the Indian Ocean area. It also suggested that these individuals were Muslims. It argued that stable isotopic analysis of burials, combined with historical and archaeological data were an effective way of investigating the migrations forced by the African Slave Trade, as well as the emergence of the underclass and working class in the Old World.
was renamed Merck Sharp & Dohme, and Schering-Plough renamed as "Merck & Co., Inc." The maneuver was an attempt to avoid a "change-of-control" in order to preserve Schering-Plough's rights to market Remicade. A settlement with Johnson & Johnson was reached in 2011, in which Merck agreed to pay $500 million. Merck Sharp & Dohme remains a subsidiary of the Merck & Co. parent. Richard Clark retired as CEO and company president in October 2011 and Kenneth Frazier became CEO. In October 2013, Merck announced it would cut 8,500 jobs in an attempt to cut $2.5 billion from its costs by 2015. Combined with 7,500 job cuts announced in 2011 and 2012, the layoffs amounted to 20% of its workforce. By 2014, research performed at Merck has led to U.S. FDA approval of 63 new molecular entities. In August 2014, Merck acquired Idenix Pharmaceuticals for $3.85 billion. In September 2014, the US Food and Drug Administration (FDA) approved Pembrolizumab (MK-3475) as a breakthrough therapy for melanoma treatment. In clinical trials, pembrolizumab provided partial tumor regression in about one quarter of patients, many of whom have not seen further progression of their disease in over 6 months of follow-up. In December 2014, the company acquired Swiss biotechnology company OncoEthix for up to $375 million. Between 2010 and 2015, the company cut around 36,450 jobs. During that time, the company sold its consumer health business to Bayer and narrowed the company's focus to immunology, vaccines, diabetes, emerging markets and medicines used in hospitals, like certain antibiotics.
On 20 September 2023, Florida outlawed tianeptine, classifying it as a schedule I substance by an administrative edict issued by the Florida Attorney General. In July 2026, the United States Drug Enforcement Administration (DEA) announced its intention to make tianeptine a Schedule I controlled substance.
A Possible start codons in NCBI table 1. ATG is most common. The two other start codons listed by table 1 (GTG and TTG) are rare in eukaryotes. Prokaryotes have less strigent start codon requirements; they are described by NCBI table 11. B ^ ^ ^ The historical basis for designating the stop codons as amber, ochre and opal is described in an autobiography by Sydney Brenner and in a historical article by Bob Edgar.
Sources: en.wikipedia.org
== Ecological considerations == Because of the beneficial uses of KLH, the Giant Keyhole Limpet, from which KLH is derived, has been a subject of growing concern among fisheries biologists in the state of California due to the possibility of overharvest of the species for commercial purposes. Giant Keyhole Limpets are not an abundant species to begin with, and some divers have reported a decline in their populations. In a 2006 report from the Marine Science Institute, University of California, Santa Barbara, scientists state that they are "very concerned about the emerging fishery" for Giant Keyhole Limpets and suggest the potential exists to "decimate their populations". To help assure a secure long-term source of KLH for the many Federally sponsored biomedical research programs using KLH, Federal agencies including the National Institutes of Health and the National Science Foundation have also sponsored research to establish sustainable mariculture production of the Giant Keyhole Limpet.
Numerous analogues and derivatives of DMT are known. Some examples include tryptamine (T), N-methyltryptamine (NMT), serotonin (5-hydroxytryptamine; 5-HT), psilocin (4-HO-DMT), psilocybin (4-PO-DMT), 4-AcO-DMT (psilacetin), 4-PrO-DMT, bufotenin (5-HO-DMT or N,N-dimethylserotonin), and 5-MeO-DMT (mebufotenin; N,N,O-trimethylserotonin). Some further examples include methylethyltryptamine (MET), diethyltryptamine (DET), methylpropyltryptamine (MPT), dipropyltryptamine (DPT), methylisopropyltryptamine (MiPT), diisopropyltryptamine (DiPT), methylallyltryptamine (MALT), diallyltryptamine (DALT), and pyr-T (N,N-tetramethylenetryptamine) and their derivatives. Some lesser-known DMT derivatives include 1-methyl-DMT, lespedamine (1-MeO-DMT), 2-methyl-DMT, 4-methyl-DMT, 4-MeO-DMT, 4-fluoro-DMT, 5-methyl-DMT, 5-ethyl-DMT, 5-TFM-DMT, 5-EtO-DMT, 5-TFMO-DMT, 5-fluoro-DMT, 5-chloro-DMT, 5-bromo-DMT, 6-fluoro-DMT, 5,6-dibromo-DMT, 4,5-MDO-DMT, 4,5-DHP-DMT, 5,6-MDO-DMT, 5-MeS-DMT, 6-methyl-DMT, 6-HO-DMT, 6-MeO-DMT, 7-methyl-DMT, 7-MeO-DMT, NBoc-DMT (NB-DMT), α,N,N-TMT (α-Me-DMT), and α,N,N,O-TeMS (5-MeO-α-Me-DMT). Cyclized tryptamines containing DMT in their chemical structures include ibogalogs like ibogainalog and tabernanthalog; iboga alkaloids like ibogaine and noribogaine; lysergamides like ergine (LSA) and lysergic acid diethylamide (LSD); and partial ergolines and lysergamides like N-DEAOP-NMT, 10,11-seco-LSD, RU-28306 (4,α-methylene-DMT), RU-28251 (4,α-methylene-DPT), Bay R 1531 (LY-197206; 4,α-methylene-5-MeO-DPT), and NDTDI (8,10-seco-LSD), among others.
13 September Space - the Final Junkyard, about space debris; Nick Johnson of NASA; Paul Maley of United Space Alliance, and JSC Astronomical Society; Mark Mulrooney of the NASA Orbital Debris Observatory, and its liquid-mirror telescope; Scott J. Horowitz; Pam McCraw of Mission Operations Directorate at the Johnson Space Center in Texas; the Institute for Advanced Technology at the University of Texas at Austin; Richard Crowther of the Defence Evaluation and Research Agency; Don Kessler of NASA JSC; the French reconnaissance Cerise (satellite), which was damaged on 24 July 1996 by debris from Ariane; Darren McKnight and Kosmos 1275, launched on 4 June 1981, and was damaged on 24 July 1981; on 24 January 1978, the nuclear-powered Kosmos 954, a RORSAT, crashed into Canada; The Aerospace Corporation; the Russian Mars 96 was launched on 16 November 1996, to hopefully reach Mars on 12 September 1997, but re-entered the atmosphere east of Iquique in north Chile on 17 November 1997, carrying 270g of plutonium; as part of NASA's Systems for Nuclear Auxiliary Power, the satellite Transit 5BN-3 with a SNAP-9A nuclear power source, launched from Vandenberg Air Force Base (since May 2021, Vandenberg Space Force Base) in California, and never reached orbit on 21 April 1964, dispersing 1 kg of plutonium-238; the Iridium satellite constellation of 66 telecommunication satellites and the proposed Teledesic scheme; a damaged satellite could cause the catastrophic Kessler syndrome; John Muratore and the NASA X-38.
In addition to hunting spiders, Batozonellus maculifrons wasps also hunt a large variety of insects. The animals within this genus use both the α-PMTX and β-PMTX. As of date, the wasp has only been reported in China and Japan.
== History == Salvia divinorum has been used as an entheogen by the Mazatec people of Mexico for hundreds of years. The American anthropologist Jean Bassett Johnson made expeditions to Mexico in the mid-to-late 1930s, observed the entheogenic use of Salvia divinorum by the Mazatecs there, and was the first to describe the existence of the plant in 1939. Subsequently, other researchers, including Blas Pablo Reko and Robert J. Weitlaner, also described the plant and its use in the 1940s and 1950s. Arturo Gómez-Pompa classified the plant as belonging to the genus Salvia in 1957, but was unable to completely identify it at the time due to absence of flowering material. Finally, Robert Gordon Wasson and Albert Hofmann collected flowering specimens of the plant in the early 1960s and sent them to Carl Epling, the leading expert on the Salvia genus of the time, who defined the plant as a new species named Salvia divinorum in 1962. Salvinorin A was isolated from Salvia divinorum and identified by Alfredo Ortega and colleagues in 1982. They used a combination of spectroscopy and X-ray crystallography to determine the chemical structure of the compound, which was shown to have a bicyclic diterpene structure. Around the same time, Leander Julián Valdés III independently isolated the molecule as part of his doctoral research, published in 1983. Valdés named the chemical divinorin, and also isolated an analogue that he named divinorin B. The naming was subsequently changed to salvinorin A and salvinorin B after the work was published in 1984. Valdés later isolated salvinorin C as well.
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.